LifeMD is trading at $3.39, up 10.06%, with no reliable company-specific catalyst identified for September 8, 2026.

  • LifeMD’s latest major update was its August 5 second-quarter report, which included weaker revenue, an adjusted EBITDA loss, and reduced full-year guidance—not a fresh catalyst for this move.
  • Broader markets are weaker, so the gain does not clearly align with overall risk sentiment.